Actions of intravenous magnesium on ventricular arrhythmias caused by acute myocardial infarction.
Although the antiarrhythmic properties of magnesium are well recognized, its mechanisms of antiarrhythmic action are poorly understood. This study was designed to characterize the effects of magnesium on ventricular tachyarrhythmias related to acute myocardial infarction (MI) in dogs. When the circumflex coronary artery was occluded repeatedly for 10 min at 30-min intervals, ventricular fibrillation (VF) occurred in 30, 35 and 33% of dogs during occlusions 1, 2 and 3, respectively. Magnesium pretreatment reduced the incidence of VF to 14% during occlusion 3 (P less than .05 compared to occlusions without magnesium pretreatment). Neither the prevalence of ventricular ectopic complexes 24 h after MI nor arrhythmia inducibility 4 days after infarction were significantly altered by i.v. magnesium. Magnesium significantly attenuated the ST segment elevation (an index of ischemic injury) and ventricular conduction slowing caused by MI. Because magnesium has been reported to reverse the effects of hyperkalemia, we evaluated the role of this action by infusing potassium directly into a coronary artery (to mimic ischemia-induced hyperkalemia) and administered i.v. magnesium. Potassium infusion markedly slowed intraventricular conduction, an effect fully reversed by discontinuing potassium administration but unaffected by i.v. magnesium. We conclude that magnesium has antiarrhythmic actions only during the early phases of an experimental MI, and that these actions are associated with attenuation of indices of ischemic injury and conduction slowing. These properties of magnesium are similar to those of calcium antagonists, and suggest that magnesium's calcium antagonist properties may be important in its antiarrhythmic actions.
Department of Medicine, Montreal Heart Institute, Canada.
S
S
Nattel
N
N
Turmel
R
R
Macleod
B C
BC
Solymoss
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology; D003327:Coronary Disease / Q000150:complications; D004285:Dogs; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology; D006934:Hypercalcemia / Q000150:complications; D008274:Magnesium / Q000097:blood / Q000494:pharmacology*; D015636:Magnesium Chloride / Q000008:administration & dosage; D008297:Male; D009203:Myocardial Infarction / Q000150:complications*; D013610:Tachycardia / Q000188:drug therapy / Q000209:etiology; D016276:Ventricular Function / Q000187:drug effects
D015636:Magnesium Chloride; D008274:Magnesium